Search

Major bleeding in patients on treatment with NOACs or VKAs in real-life: clinical presentation, management and outcome

Major bleeding in patients on treatment with NOACs or VKAs in real-life: clinical presentation, management and outcome

Limited data are available on major bleeding (MB) occurring during treatment with vitamin K (VKAs) or non-vitamin K antagonist oral anticoagulants (NOACs) outside clinical…

Read more

Dr A van Hylckama Vlieg Announced Winner of the first EHA-ISTH Joint Fellowship

The award of EUR 72,000 over two years is intended to support the study of the physiology of bleeding, coagulation or thrombosis. Dr.

Read more

Meeting program

Saturday, November 4*All times are in EET.

Read more

Does the patient with myelofibrosis feel better through Pacritinib?

Pacritinib is an oral next-generation multikinase inhibitor with specificity for JAK2 and FLT3 being evaluated to treat myelofibrosis in two Phase 3 trials.

Read more

First CMML guidelines produced by EHA, now available

Chronic myelomonocytic leukemia (CMML) is a rare disease with overlapping features of two categories of bone marrow and blood cell disorders that poses challenges in clinical management.

Read more

EHA Pediatric Hemato-Oncology Course programme

April 10, 202414:00–17:30: Red Cell and ConsultativeWelcome and presentation of the course.  Aims, expectations, and a brief look back. Presenters and topics
M. de Montalembert: Difficult management problems in sickle cell disease
M. D.

Read more

Expert opinions for specific non-malignant hematologic diseases

Red Cells and Iron
Hemoglobinopathies: Sickle Cell Disease and Thalassemia

Sickle Cell Disease Association of America (SCDSS)
Sickle Cell Disease and COVID-19: An Outline to Decrease Burden and Minimize Morbidity 
Italian Society of Thalassemia and Hemoglobinopathies

Thalassemia and Hemoglobin disorders Italian Society
Thalassemia International Federation (TIF)
The COVID-19…

Read more

100,000 Patient data sets: The value of data sharing to accelerate blood cancer research.

With almost 100,000 patient data sets identified and 63,000 already transferred to the HARMONY Big Data Platform, the HARMONY Alliance is fully equipped to facilitate state-of-the-art research into blood cancers.

Read more